

Organized by:



In collaboration with:



Under the auspices of:



# MELANOMA bridge 2023

Naples (Italy)

November 30<sup>th</sup> - December 2<sup>nd</sup>, 2023

Aula Magna - Università degli Studi di Napoli Federico II  
Via Partenope 36, Napoli

# 2023

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING SECRETARIAT:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

Only registered attendees will be admitted to the meeting.


The registration fee includes:

- participation in the scientific sessions
- congress kit (badge, notepad, pen)
- coffee breaks and lunches from Nov 30<sup>th</sup> to Dec 2<sup>nd</sup>

# GENERAL INFORMATION

## CONGRESS VENUE:

Aula Magna - Università degli Studi di Napoli Federico II  
Via Partenope 36, Napoli  
80121 - Naples



AIRPORT

RAILWAY STATION

CONGRESS  
VENUE

# SCIENTIFIC RATIONAL

---

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune - and target - therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the "Great Debate" sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

# SCIENTIFIC PROGRAM

Thursday, Nov 30<sup>th</sup>, 2023



05:30 pm | *Registration\*\**

**MELANOMA BRIDGE OPENING SESSION\*\***

*Chairpersons: Paolo A. Ascierto, Francesco Marincola*

06:15 pm | Melanoma Screening: Rethinking the benefits and harms\*\*

**Laura K. Ferris**

06:30 pm | Artificial intelligence in melanoma research: the pros and cons\*\*

**Iman Osman**

06:50 pm | Immunotherapy Resistance - What Resistance? \*\*

**Samir N. Khleif**

07:10 pm | Advocacy the World Over\*\*

**Samantha Guild, Claudia Piazza Cidonio**

2023

*\*Speakers invited*

*\*\*Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

Friday, Dec 1<sup>st</sup>, 2023



09:20 am	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SESSION 1</b> <b>MELANOMA IS MODEL FOR CANCER IMMUNOTHERAPY</b> <i>Chairpersons: Magdalena Thurin, Lisa Villabona</i>
09:30 am	Expectations, concerns, and the unknown - A SITC perspective on survivorship following Immune Checkpoint Inhibitor therapy for Patients with Cancer <b>Marc S. Ernstoff</b>
09:45 am	Q&A
09:50 am	The next steps to fully personalized neo adjuvant immunology in melanoma <b>Christian Blank</b>
10:05 am	Q&A
10:10 am	Is Seeing Believing with Immunotherapy? <b>Michael A. Postow</b>
10:25 am	Q&A
10:30 am	New interesting target from recent research <b>Omid Hamid</b>
10:45 am	Q&A
10:50 am	<i>Coffee break**</i>
11:05 am	IO toxicities and management <b>Ryan Sullivan</b>
11:20 am	Q&A
11:25 am	Targeting TLR9 for the Treatment of Melanoma <b>Anna Pavlick</b>
11:40 am	Q&A
11:45 am	<b>SYMPOSIUM - Adjuvant therapies for stage II melanoma</b> <b>Ana M. Arance, Paolo A. Ascierto</b>
12:35 pm	<i>Lunch**</i>

*\*Speakers invited*

*\*\*Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

Friday, Dec 1<sup>st</sup>, 2023



## SESSION 2

### MELANOMA TUMOR BIOLOGY

*Chairpersons: Michele Del Vecchio, Mario Mandalà*

- 01:35 pm Identification of novel phosphopeptide neoantigens for cancer immunotherapy  
**Michelle Krogsgaard**
- 01:50 pm Lymphatic Transport Conditions Lymph Nodes for Metastasis  
**Amanda W. Lund**
- 02:05 pm Melanoma biology in the context of clinical and experimental resistance  
**Roger S. Lo**
- 02:20 pm Stability of the Gut Microbiota during Anti-PD1 Immunotherapy Defines Complete Response in Melanoma Patients  
**Luigi Nezi**
- 02:35 pm Designing tumor-selective therapeutic strategies for RAS pathway-driven cancers  
**Poulikos I. Poulikakos**
- 02:50 pm Discussion

03:10 pm **SYMPOSIUM - The new era of target therapy in metastatic melanoma: sequencing and beyond**  
**Paolo A. Ascierto, Reinhard Dummer**

04:00 pm *Coffee break\*\**

## GREAT DEBATE SESSION

*Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori*

- 04:15 pm Brain metastases treatment: Car-T cell therapy VS Car-NK cell therapy  
**Hussein A. Tawbi VS Mayra Shanley**
- 04:45 pm Discussion
- 04:55 pm Is SLN biopsy NO longer necessary for patients with high risk primary cutaneous melanoma in an era of effective adjuvant immunotherapy? Yes or No  
**Jason J. Luke VS Jeffrey E. Gershenwald**
- 05:25 pm Discussion
- 05:35 pm Clinical drugs development phase 1-2-3 VS novel trials design  
**Igor Puzanov VS Mustafa Khasraw**
- 06:05 pm Discussion
- 06:15 pm Radiomics VS molecular imaging  
**Marius E. Mayerhoefer VS Simone Krebs**
- 06:45 am Discussion

*\*Speakers invited*

*\*\*Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

Saturday, Dec 2<sup>nd</sup>, 2023



## SESSION 3

### EMERGENT STRATEGIES

*Chairpersons:* **Mario Mandalà, Giuseppe Palmieri**

- 09:30 am Novel Adjuvant and Neoadjuvant Approaches: Which are poised to change practice?  
**Janice M. Mehnert**
- 09:45 am Q&A
- 09:50 am mRNA neoantigen vaccines for high risk melanoma  
**Jeffrey S. Weber**
- 10:05 am Q&A
- 10:10 am Major shift in melanoma management are emerging: high risk for relapse identification in primary melanomas and neoadjuvant immunotherapy developments  
**Alexander M.M. Eggermont**
- 10:25 am Q&A
- 10:30 am Uveal Melanoma  
**Richard D. Carvajal**
- 10:45 am Q&A
- 10:50 am Engineered T cells  
**Olivier Michielin**
- 11:05 am Q&A
- 11:10 am Novel technologies and systems innovation in modern melanoma care  
**Thach-Giao Truong**
- 11:25 am Q&A
- 11:30 am Non-immune based therapy in the BRAFv600 WT melanoma  
**Jeffrey A. Sosman**
- 11:45 am Q&A
- 11:50 am *Coffee break\*\**

*\*Speakers invited*

*\*\*Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

Saturday, Dec 2<sup>nd</sup>, 2023



12:10 pm	<b>SYMPOSIUM</b> Adjuvant and Neo-adjuvant, <b>Dirk Schadendorf</b> Metastatic Melanoma, <b>Paolo A. Ascierto</b>
01:00 pm	Lunch**
02:00 pm	<b>SYMPOSIUM - Breaking boundaries with new era of therapeutic cancer vaccines building on CPIs</b> Chairperson: <b>Paolo A. Ascierto</b> <b>Michael A. Postow, Ryan Sullivan</b>
	<b>GREAT DEBATE SESSION</b> Chairpersons: <b>Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov</b>
02:50 pm	Biomarkers Directing melanoma immunotherapy: useful or not useful? <b>Jeffrey A. Sosman VS Alexander M.M. Eggermont</b>
03:20 pm	Discussion
03:30 pm	What is better treatment for PD-1 refractory melanoma? Tumor infiltrating lymphocyte therapy vs nivolumab + ipilimumab <b>Allison Betof Warner VS James Smithy</b>
04:00 pm	Discussion
04:10 pm	What is the best initial treatment for unresectable mucosal melanoma? Nivolumab + ipilimumab VS PD-1 + VEGF inhibition <b>Alexander Shoushtari VS Jason J. Luke</b>
04:40 pm	Discussion
04:50 pm	Putting it all together - Practical Considerations for Monday Clinic <b>Sanjiv S. Agarwala</b>
05:05 pm	Conclusions <b>Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov</b>

\*Speakers invited

\*\*Not included in the CME accredited program

## PRESIDENCY

---



### **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy



### **Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy



### **Iman Osman**

Rudolf Baer Professor of Dermatology; Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US



### **Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

## SCIENTIFIC BOARD

### **Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

### **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

### **Carlo Bifulco**

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

### **Elizabeth M. Burton**

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

### **Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

### **Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

### **Mary Dean**

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

### **Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

# SCIENTIFIC BOARD

---

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Alexander M.M. Eggermont**

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, The Netherlands

**Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center – Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Claus Garbe**

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

**Jeffrey E. Gershenwald**

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin**

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

**Iman Osman**

Rudolf Baer Professor of Dermatology; Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Tara Withington**

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# FACULTY

---

**Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

**Ana M. Arance**

Accredited Researcher, Clinic Barcelona, Barcelona, Spain

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Allison Betof Warner**

Assistant Professor of Medicine (Oncology), Director, Melanoma Medical Oncology Program, Director, Solid Tumor Cellular Therapy Leader, Melanoma & Cutaneous Oncology Clinical Research Group, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, US

**Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Richard D. Carvajal**

Deputy Physician-in-Chief and Director, Hematology and Medical Oncology, Northwell Health Cancer Institute, Lake Success, NY

**Michele Del Vecchio**

Responsabile SS Oncologia Medica Melanomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Alexander M.M. Eggermont**

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical & Translational Immunotherapy, Utrecht University, Utrecht, The Netherlands

**Marc S. Ernstoff**

Branch Chief, ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Cancer Therapy & Diagnosis Division, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Laura K. Ferris**

Director of Clinical Trials, UPMC Department of Dermatology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, US

**Jeffrey E. Gershenwald**

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

**Samantha Guild**

President AIM at Melanoma Richmond, CA, US

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Mustafa Khasraw**

Professor of Neurosurgery, Professor in Medicine, Member of the Duke Cancer Institute, Durham, NC, USA

**Samir N. Khleif**

Director of the Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

**Simone Krebs**

Assistant Attending Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

# FACULTY

---

**Michelle Krosgaard**

Associate Professor of Pathology, Co-leader of Tumor Immunology Program, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

**Roger S. Lo**

Professor of Medicine/Dermatology, Associate Chief of Dermatology, Director of the Dermatology STAR Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, US

**Jason J. Luke**

Director, Immunotherapy and Drug Development Center, Associate Professor of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, US

**Amanda W. Lund**

Associate Professor, Ronald O. Perelman Department of Dermatology, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY US

**Mario Mandalà**

Associate Professor of Medical Oncology, University of Perugia, Perugia, Italy

**Francesco Marincola**

Chief Scientific Officer, Sonata Therapeutics, Watertown, MA, US

**Marius E. Mayerhoefer**

Member of the Faculty, Department of Radiology, NYU Grossman School of Medicine, New York, NY, US

**Janice M. Mehnert**

Professor of Medicine, Associate Director for Clinical Research, Laura and Isaac Perlmutter Cancer Center, Director, Melanoma and Cutaneous Medical Oncology, NYU Grossman School of Medicine, New York, NY, US

**Olivier Michielin**

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

**Luigi Nezi**

Group leader for Microbiome and T Cell Metabolism in Cancer, IEO- Istituto Europeo di Oncologia Milan, Italy

**Iman Osman**

Rudolf Baer Professor of Dermatology; Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

**Anna Pavlick**

Director, WCM Melanoma and Cutaneous Oncology Program, Weill Cornell Medical College, New York, NY, US

**Claudia Piazza Cidonio**

Co-Founder, Melanoma Italia Onlus, Rome, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Poulikos I. Poulikakos**

Professor, Department of Oncological Sciences, Precision Immunology Institute, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Dirk Schadendorf**

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

# FACULTY

---

**Mayra Shanley**

Principal Research Scientist, Stem Cell Transplantation Department, MD Anderson Cancer Center, Houston, TX, US

**Alexander Shoushtari**

Clinical Director, Melanoma Service; Member, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**James Smithy**

Assistant Attending Physician Melanoma & Cellular Therapy Services Memorial Sloan Kettering Cancer Center, New York, NY, US

**Jeffrey A. Sosman**

Professor of Medicine, Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, US

**Ryan Sullivan**

Associate Professor of Medicine, Harvard Medical School; Associate Professor of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, US

**Hussein A. Tawbi**

Deputy Chair and Director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, Co-Director, MD Anderson Brain Metastasis Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Alessandro Testori**

Chairman surgical subgroup, EORTC Melanoma Group, Brussels, Belgium

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Thach-Giao Truong**

Melanoma Program Medical Director, Cleveland Clinic, Cleveland, OH, US

**Lisa Villabona**

Affiliated to Research and Oncology Specialist, Department of Oncology-Pathology, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Jeffrey S. Weber**

Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, US

## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge Congress has been accredited (ID CME 327- 396007) with 4,2 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and Gender medicine", belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses, pediatric nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day);
2. Complete the evaluation form at the end of the Congress.

CME certificate will be sent at the end of the validation procedure.

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Melanoma Bridge is sponsored by an unrestricted grant from:

---

**PLATINUM SPONSOR**



**GOLD SPONSOR**



**SILVER SPONSOR**

IMMUNOCORE



**SPONSOR**

